#DryAMD
LightNews LightNews
psbloom.bsky.social
Great to see a Phase II #trial of #oral treatment for Geographic Atrophy (late stage #dryAMD) 🧪💊 @boehringerglobal.bsky.social www.boehringer-ingelheim.com/science-inno...
www.boehringer-ingelheim.com
May 7, 2025 at 12:43 PM
umasschan.bsky.social
New UMass Chan Medical School research reveals how a gene-silencing therapy targeting age-related macular degeneration could pause visual decline: direc.to/oKRA

#ophthalmology #MacularDegeneration #DryAMD #WetAMD #siRNA #GeneTherapy @rti-umasschan.bsky.social @moltherapy.bsky.social
New siRNA therapy has potential to halt vision loss in age-related macular degeneration
The siRNA-based therapy specifically targets photoreceptor cells in the eye, halting disease progression for six months to a year.
direc.to
May 27, 2026 at 1:31 PM
haoyin.bsky.social
#DryAMD #AgerelatedMacularDegeneration

Rat focal #ChoroidAtropy◀️NaIO3 into suprachoroidal space
⏬Choroid thickness
⏬vessel density/junctions

partial rescued by #hiPSC-#EndothelialCell transplant 7 dpi
👉making 30~40% of choroid vessels

#AdvSci 2025
advanced.onlinelibrary.wiley.com/doi/10.1002/...
September 24, 2025 at 12:24 PM
ophthalmologymg.bsky.social
Alcon announced it will acquire LumiThera, Inc., a developer of photobiomodulation (PBM) therapy for dry AMD, in a move that broadens its retinal treatment portfolio beyond surgery. Learn more here: ow.ly/2MJR50WnyRO.
#dryAMD #Alcon #LumiThera #photobiomodulation #PBM
July 10, 2025 at 12:33 PM
consumerwatch.bsky.social
NIH scientists test in an Animal Model a Surgical Technique to Improve Cell Therapy For Dry AMD 🔬 The Technique May Enable Higher Doses and Combinations of Cell Therapies. 👨‍🔬

Read Article
www.nih.gov/news-events/...

#NIH #HealthTips #Scientists #TEST #Animal #CellTherapy #DryAMD #AMD #CellHealth
May 22, 2025 at 6:04 PM
andrewlloydala.bsky.social
💥[ALA Client News] Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye

👉 ala.associates/clinical/dry...

#DryAMD #Ophthalmology #ClinicalTrial #Biotech
January 29, 2025 at 10:09 AM
4040rec.bsky.social
#Ophthalmology #clinicaltrial #dryAMDtreatment #PST611 #PulseSightTherapeutics #phase1safetystudy #genetherapy #geographicatrophy #GA #nonviralgenetherapy #dryagerelatedmaculardegeneration #AMD #DryAMD #PST611CT1study #electrotransfectiontechnology #DNAplasmids
pharmatimes.com/news/first-p...
First patient dosed in trial for novel dry AMD treatment PST-611 - PharmaTimes
PulseSight begins phase 1 safety study of gene therapy for geographic atrophy
pharmatimes.com
July 10, 2025 at 10:17 AM
seeingwithsound.bsky.social
https://www.pixium-vision.com/2021/10/poster-presented-on-thursday-october-21-2021-during-2nd-annual-dryamd-therapeutic-development-summit/
Pixium | Science Corporation
Science Corporation is a clinical-stage medical technolog...
www.pixium-vision.com
April 7, 2025 at 7:27 AM
seeingwithsound.bsky.social
Pixium Vision presented the long-term visual results of the Prima chip in patients with geographic atrophy at the 2nd Annual DryAMD Therapeutic Development Summit...
April 7, 2025 at 7:22 AM
prof-clark.bsky.social
Could Ginkgo biloba help target complement dysregulation in dry AMD? New computational evidence identifies potential disease-relevant interactions. #AMD #DryAMD #VisionScience #DrugDiscovery buff.ly/4MPNPCw
Complement-Modulating Mechanisms of Ginkgo biloba Extract in Dry AMD: Insights From Molecular Docking and Dynamics Simulations - PubMed
Because the blood-retinal barrier limits the efficacy of systemic drugs for retinal diseases, nanomaterial-based ocular delivery systems are gaining attention. However, identifying suitable bioactive…
buff.ly
June 9, 2026 at 9:00 AM
prof-clark.bsky.social
Prelim Phase 2 data hint Ocugen’s AAV5 gene therapy (OCU410) may outperform approved GA treatments at mid-dose, while higher doses raise intriguing biology questions 👀🧬 #GeneTherapy #DryAMD #GeographicAtrophy #Biotech #ClinicalTrials
Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas
Ocugen has reported preliminary phase 2 data on its e | Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform…
buff.ly
January 16, 2026 at 10:00 AM
prof-clark.bsky.social
Alcon has acquired the Valeda photobiomodulation devise, using low-level light to help stimulate mitochondrial activity in the cells of the retina, marking a pivotal expansion into non-invasive therapies for early and intermediate dry AMD. #DryAMD
Alcon to buy LumiThera’s light-based therapy for dry AMD
Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach…
buff.ly
July 11, 2025 at 2:24 AM
ophthalmicpro.bsky.social
Mary Pat Johnson, COMT, CPC, COE, CPMA, Corcoran Consulting Group, discusses the procedure and the documentation, coding and coverage instructions for billing for Photobiomodulation (PBM). ow.ly/VEYa50WNWaW #Photobiomodulation #DryAMD #ophthalmology #eyecare
September 4, 2025 at 12:29 PM
longevitytech.bsky.social
Cirrus Therapeutics lands seed funding to advance gene therapy designed to prevent and reverse dry AMD by rejuvenating the retina.

longevity.technology/news/gene-th...

#longevity #aging #biotech #visionloss #dryAMD #genetherapy #investment
October 3, 2025 at 5:00 PM
longevitytech.bsky.social
Could gene therapy trial halt vision loss?

#longevity #biotech #genetherapy #dryAMD #visionloss 

longevity.technology/news/pulsesi...
July 7, 2025 at 5:29 PM